Evidence map›Paper›PMID 35320695›Full record

ReviewAnnual review of chemical and biomolecular engineering2022

Advances in Manufacturing Cardiomyocytes from Human Pluripotent Stem Cells.

Martha E Floy, Fathima Shabnam, Aaron D Simmons, Vijesh J Bhute, Gyuhyung Jin, Will A Friedrich, Alexandra B Steinberg, Sean P Palecek

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annual review of chemical and biomolecular engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Martha E FloyDepartment of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA; email: mefloy@wisc.edu, shabnam@wisc.edu, adsimmons2@wisc.edu, wfriedrich@wisc.edu, absteinberg4@wisc.edu, sppalecek@wisc.edu.
Fathima ShabnamDepartment of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA; email: mefloy@wisc.edu, shabnam@wisc.edu, adsimmons2@wisc.edu, wfriedrich@wisc.edu, absteinberg4@wisc.edu, sppalecek@wisc.edu.
Aaron D SimmonsDepartment of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA; email: mefloy@wisc.edu, shabnam@wisc.edu, adsimmons2@wisc.edu, wfriedrich@wisc.edu, absteinberg4@wisc.edu, sppalecek@wisc.edu.
Vijesh J BhuteDepartment of Medical Genetics, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Gyuhyung JinDepartment of Chemical Engineering, Purdue University, West Lafayette, Indiana, USA; email: jin443@purdue.edu.
Will A FriedrichDepartment of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA; email: mefloy@wisc.edu, shabnam@wisc.edu, adsimmons2@wisc.edu, wfriedrich@wisc.edu, absteinberg4@wisc.edu, sppalecek@wisc.edu.
Alexandra B SteinbergDepartment of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA; email: mefloy@wisc.edu, shabnam@wisc.edu, adsimmons2@wisc.edu, wfriedrich@wisc.edu, absteinberg4@wisc.edu, sppalecek@wisc.edu.
Sean P PalecekDepartment of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA; email: mefloy@wisc.edu, shabnam@wisc.edu, adsimmons2@wisc.edu, wfriedrich@wisc.edu, absteinberg4@wisc.edu, sppalecek@wisc.edu.

Funding

BIOTECHNOLOGY TRAINING PROGRAMT32GM008349 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI FOX, BRIAN G · 1989 to 2019
$22.5M
A Multi-Omics Approach to Discover Metabolic Critical Quality Attributes for Cardiomyocyte BiomanufacturingR01HL148059 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI PALECEK, SEAN P · 2019 to 2022
$1.5M
NHLBI NIH HHS R01 HL148059NIGMS NIH HHS T32 GM008349
6 · The paper itself

Abstract

The emergence of human pluripotent stem cell (hPSC) technology over the past two decades has provided a source of normal and diseased human cells for a wide variety of in vitro and in vivo applications. Notably, hPSC-derived cardiomyocytes (hPSC-CMs) are widely used to model human heart development and disease and are in clinical trials for treating heart disease. The success of hPSC-CMs in these applications requires robust, scalable approaches to manufacture large numbers of safe and potent cells. Although significant advances have been made over the past decade in improving the purity and yield of hPSC-CMs and scaling the differentiation process from 2D to 3D, efforts to induce maturation phenotypes during manufacturing have been slow. Process monitoring and closed-loop manufacturing strategies are just being developed. We discuss recent advances in hPSC-CM manufacturing, including differentiation process development and scaling and downstream processes as well as separation and stabilization.

Indexed as

Myocytes, CardiacPluripotent Stem CellsCell DifferentiationHumansbioreactorscardiomyocyteshPSChuman pluripotent stem cellsmanufacturingquality attributesscale-upstem cells

Identifiers

PMID35320695
PMCPMC9197878

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.